Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.51 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 7/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5653496 | 0.97 | SIRT6 (0.52) | SIRT6LMNAMAPTHTTAR | |
| SCHEMBL5653501 | 0.97 | SIRT6 (0.52) | SIRT6LMNAMAPTHTTAR | |
| SCHEMBL14393465 | 0.85 | SIRT6 (0.52) | SIRT6LMNAMAPTHTTAR | |
| SCHEMBL5651997 | 0.85 | SIRT6 (0.52) | SIRT6LMNAMAPTHTTAR | |
| SCHEMBL5652684 | 0.84 | SIRT6 (0.47) | SIRT6LMNAMAPTHTTAR | |
| SCHEMBL18950212 | 0.81 | SIRT6 (0.50) | SIRT6LMNAMAPTHTTAR | |
| SCHEMBL9300689 | 0.80 | HPGD (0.56) | CUL4ALMNAMAPTHTTMEN1 | |
| SCHEMBL27262497 | 0.80 | MAPT (0.50) | SIRT6CUL4ALMNAMAPTHTT | |
| SCHEMBL16181627 | 0.80 | RAB9A (0.41) | LMNAARRAB9A | |
| SCHEMBL5652569 | 0.80 | SIRT6 (0.48) | SIRT6LMNAMAPTHTTAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359285-B2 | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2016-06-07 | — | — | US | disclosed |
| US-20150099720-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-04-09 | — | — | US | disclosed |
| US-8865918-B2 | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-10-21 | — | — | US | disclosed |
| US-8519158-B2 | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-20070254875-A1 | Androgen Receptor Modulator Compounds and Methods | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099720-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | AR, SHBG, NR5A1 | SIRT6 1577/4885CUL4A 3575/4885LMNA 3870/4885 |
| US-20070254875-A1 | Androgen Receptor Modulator Compounds and Methods | AR, SHBG, NR5A1 | SIRT6 1577/4885CUL4A 3575/4885LMNA 3870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.